To identify changes in health-related quality of life (HRQoL) after diagnosis of bladder cancer in older adults in comparison with a group of adults without bladder cancer (controls).
Introduction
Bladder cancer is the fifth most common cancer, with 77 000 new cases in 2016, and an estimated 587 426 living with the disease in the USA [1] . Muscle-invasive bladder cancer (MIBC) disease requires radical surgical treatment or chemoradiation with intensive surveillance. Although less severe, non-muscle-invasive bladder cancer (NMIBC) requires longterm surveillance with periodic cystoscopy and intravesical therapy. Intense treatment and surveillance may negatively affect health-related quality of life (HRQoL).
To date, research on HRQoL for patients with bladder cancer has been limited, with retrospective studies investigating treatment differences within cohorts of patients with NMIBC and MIBC. Among patients with MIBC undergoing cystectomy, HRQoL has been compared for different diversion types [2, 3] , while HRQoL for patients with NMIBC has been studied with regard to various intravesical treatments [4] . A limitation in the current understanding of HRQoL among patients with bladder cancer is how patients' HRQoL changes after diagnosis. This is critical for patients with bladder cancer, given that the disease is prevalent in older adults who face other threats (i.e. comorbidities) to HRQoL. A previous study investigating the impact of cancer diagnosis on HRQoL in several cancers reported significant declines in physical health among patients with bladder cancer compared with control subjects [5] ; however, the impact of treatment, disease stage and time since diagnosis on HRQoL specific to patients with bladder cancer was not reported.
To our knowledge, no prospective study has investigated the impact of bladder cancer diagnosis on HRQoL using health status assessments before cancer diagnosis and assessing the impact of time since diagnosis, treatment type and stage. The objective of the present study was to compare prospective HRQoL changes in a group of patients diagnosed with bladder cancer with changes among matched control subjects without cancer, drawn from the same population. We hypothesized that patients with bladder cancer, regardless of disease stage or treatment, would self-report HRQoL declines, and these would be most pronounced among those with invasive disease receiving aggressive treatment.
Materials and Methods

Study Participants
The present study included patients with new incident bladder cancer aged ≥65 years who were enrolled in Medicare Advantage managed care plans. Data from the Centers for Medicare and Medicaid Services' Medicare Health Outcomes Survey (MHOS) were linked with the Surveillance, Epidemiology and End Results (SEER) cancer registries provided by the National Cancer Institute. The MHOS is an annual survey administered to a random sample of 1 000-1 200 Medicare beneficiaries from each managed care plan [6] . Each participant is asked to complete a baseline survey and a follow-up survey 2 years later if they are enrolled in the same plan. Cancer-specific information is collected on patients with newly diagnosed cancer within specified geographic regions through the SEER programme. The SEER-MHOS linkage is described elsewhere [7] . We obtained institutional review board permission for secondary data analysis from the University of North Carolina at Chapel Hill.
Our study included 14 MHOS cohorts with baseline assessments from the period 1998-2011 and follow-up assessments from the period 2000-2013 [8] . We identified 535 individuals who completed both baseline and follow-up MHOS and were diagnosed with bladder cancer between assessments. To evaluate prospectively the impact of a bladder cancer diagnosis on HRQoL, we selected control subjects without cancer who responded to both baseline and follow-up MHOS, resided in the same SEER region, and participated in the same managed care plans as the patients with bladder cancer. Using propensity scores, we matched five controls to each case to balance the proportion of patient and survey characteristics between the groups. Propensity score matching was performed using baseline age, race, education, region, marital status, proxy status, assessment mode, smoking status, high blood pressure, heart disease, stroke, chronic obstructive pulmonary disease, inflammatory bowel disease, arthritis, sciatica, diabetes and depression [9] . This resulted in selection of 2 770 control subjects matched to 535 patients with bladder cancer.
Data Collection
The MHOS provides self-reported data on demographics (age, gender, race, smoking status, marital status), survey characteristics (self-report, proxy status, mail or telephone report), HRQoL, chronic medical conditions and health status [8] . HRQoL was self-reported using the Medical Outcomes Study 36-item short-form health survey (SF-36) on the MHOS from 1998 to 2005. Subsequently, the MHOS changed to the Veterans RAND-12 (VR-12) from 2006 to 2013. The SF-36/VR-12 includes eight subscales: physical functioning; role physical;, general health; vitality (representing energy level and fatigue); social functioning; role emotional; and mental health [10] . Each subscale produces a physical component summary (PCS) score and a mental component summary (MCS) score. SF-36/VR-12 scores were normalized to the general US population (mean AE SD is 50 AE10), with scores ranging from 0 to 100 and higher scores indicating better HRQoL. A clinically meaningful difference is noted of at least one-half standard deviation (5 points) [11] ; however, a prior study in this area defined a minimally important difference of 2 for summary measures (e.g. PCS and MCS) and 4 for subscales (e.g. vitality, social functioning) [12] .
Definitions for Treatment, Stage and Time since Diagnosis
Staging was defined using historical stage, given longitudinal changes in American Joint Committee on Cancer (AJCC) and incomplete data for the AJCC staging variable. Historical stage was dichotomized as localized (NMIBC) or muscleinvasive disease (MIBC). Treatment was defined using codes to differentiate between conservative treatment (bladder biopsy, transurethral resection of bladder tumour, partial cystectomy) and radical treatment (radical cystectomy, pelvic exenteration). Patients were stratified by time since diagnosis: 0-6, 6-12 or >12 months. These time periods were chosen to reflect early post-treatment effects, intermediate recovery after treatment, and post-treatment baseline. A sensitivity analysis using 3-month increments was also conducted, with no appreciable differences in results (Fig. S1 ). Given the low frequency of individuals who were missing pathological data (<20), patients with missing stage and treatment were excluded from the analyses.
Statistical Analysis
Analyses were conducted in R version 3.3.0 [13] . Numeric variables were scaled [14] using sample estimates. Bivariate associations were evaluated using a t-test for continuous variables and the chi-squared test for categorical variables. Using HRQoL before and after diagnosis for each subject as longitudinal outcomes necessitated a statistical approach accounting for within-subject correlation and heterogeneity
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© 2017 The Authors BJU International © 2017 BJU International amongst subjects. Hence, the linear mixed model [15, 16] for longitudinal data was employed, using restricted maximum likelihood estimation [17] . Variable interactions with time allowed estimation of both synchronous and lagged effects [18] (e.g. the effect of comorbidities at baseline on HRQoL at follow-up). Model selection was facilitated by information criteria [19] and several measures of multivariate association [20] . Least-squares mean [21] estimates facilitated group-wise comparison of HRQoL domains. Confounding effects were minimized by propensity matching using a 5-to-1 control to case ratio, based on patient demographics and pre-existing conditions. Sensitivity analyses were conducted by separately fitting a model using the full data (i.e. without propensity matching) and comparing conclusions drawn. Results from the full data model were in complete agreement with inferences made using the propensity score model (Table S1 and Figs S2-4). Additional logistic regression models were constructed to evaluate predictors of a meaningful decrease in MCS or PCS scores (defined as a decrease of ≥2 points).
Results
Study Sample
Patients were stratified by NMIBC (n = 458) and MIBC (n = 77) and compared with matched controls (n = 2 770). After propensity score matching, no statistically significant differences between cases and controls were observed based on demographic characteristics, survey characteristics, or preexisting comorbidities (Table 1 ). The mean (SD) time between surveys was 2.7 (1.9) years for cases and 2.1 (0.1) years for matched controls.
Changes in Physical Health
Adjusted HRQoL measures for physical health were compared between controls and cases based on disease stage (Table 2) . PCS scores ranged from 0 to 100, with higher scores representing better HRQoL. Changes over time in PCS scores were significantly worse in both NMIBC (Δ = À2.0; P = 0.01) and MIBC (Δ = À5.3; P < 0.01) cases compared with controls (Δ = À0.4). Similar decrements in bodily pain, role physical and general health scores were identified for cases regardless of stage (Fig. 1) ; however, changes over time in physical functioning diminished only in MIBC cases (Δ = À5.8) compared with controls (Δ = À0.3; P < 0.01).
Physical HRQoL was evaluated by treatment and time since diagnosis. Patients undergoing cystectomy reported significant HRQoL decrements across nearly all physical domains, including PCS, physical functioning, role physical and general health (Fig. 2) . Role physical scores improved over time whereas physical functioning scores deteriorated (Fig. 3 ). PCS and general health scores also appeared to decline after diagnosis and did not return to baseline.
Predictors of a significant decrease in PCS score included living in the South (odds ratio [OR] 2.6; P = 0.02) and recent diagnosis of depression (OR 4.2; P < 0.001 [ Table 3 ]). Patients with hypertension and atherosclerosis appeared to be less likely to experience significant decreases in PCS scores.
Changes in Mental Health
Adjusted mental HRQoL measures were compared between controls and cases based on disease stage ( Table 2) . MCS scores ranged from 0 to 100, with higher scores representing better HRQoL. Mean MCS score change over time did not significantly differ between NMIBC (Δ = À1.4; P = 0.08) and MIBC (Δ = À2.5; P = 0.29) cases compared with controls (Δ = À0.3 [ Fig. 1]) ; however, differences in social functioning decrements over time were noted between NMIBC (Δ = À2.1; P = 0.01) and MIBC (Δ = À5.7; P < 0.01) cases compared with controls (Δ = À0.8). Similar decrements were notable for vitality scores, with NMIBC (Δ = À1.2; P < 0.01) and MIBC (Δ = À3.5; P < 0.01) cases reporting greater declines in vitality scores compared with controls (Δ = À0.1). No significant differences in mental health or role emotional scores were observed between cases and controls.
Mental HRQoL was also compared with regard to treatment and time since diagnosis. Individuals undergoing cystectomy reported statistically significant decrements in HRQoL across several mental health domains, including role emotional, vitality and social functioning scores (Fig. 2) . With regard to time since diagnosis, several mental HRQoL domains remained stable over time, including vitality and MCS scores (Fig. 3) . Changes in social functioning score were small among cases diagnosed between 6 and 12 months and worse in the first 6 months after diagnosis and 12 months after diagnosis.
Predictors of a significant decrease in MCS score included recent depression (OR 2.8; P = 0.002), and being a former or never smoker (OR 2.9, P = 0.009; OR 2.2, P = 0.02 [ Table 3 ]). Patients with distant depression (OR 0.2; P = 0.001) or chronic sciatica (OR 0.59; P = 0.04) appeared to be less likely to experience significant decreases in MCS.
Discussion
In this prospective population-based study, we evaluated the burden of bladder cancer diagnosis and treatment on the lives of older people in the USA. We found that physical HRQoL was significantly affected by diagnosis/treatment (regardless of stage) and worse among individuals with invasive disease. Significant decrements in social functioning were also noted among patients with MIBC compared with controls without cancer. To our knowledge, this is the first study to report HRQoL changes after bladder cancer diagnosis as they relate to treatment and disease stage, compared with a matched control group of older adults without cancer.
Until recently, our understanding of HRQoL in patients with bladder cancer has been limited. A systematic review evaluating HRQoL in patients with bladder cancer concluded that most studies were retrospective and cross-sectional, and had methodological limitations such as lack of pre-diagnosis data, insufficient follow-up duration, and small sample size [22] . Although specific HRQoL differences between urinary diversion were evaluated, differences by time since diagnosis and management strategies were not considered [23] . Since publication of the systematic review, additional studies have emerged, which shed light on general and cancer-specific HRQoL among patients with bladder cancer [5, 24] . Notably, the HRQoL of patients with bladder cancer was previously evaluated using SEER-MHOS, but in a limited capacity [5] . These studies investigated nine to 12 cancer sites (including bladder) and compared patients with cancer with control subjects without cancer, with limited detail regarding specific cancer types [5, 25] . Results were similar in that physical health status decreased more than mental health across all cancer domains [5] , and physical health status after diagnosis was worse among patients with cancer [25] . In another study which evaluated bladder cancer specifically in the SEER-MHOS, differences in PCS and MCS scores were investigated by comparing two cohorts: patients who completed the MHOS before diagnosis and individuals who completed the MHOS after diagnosis [24] . Although significant declines in PCS and MCS scores were observed, a limitation of this cross-sectional study was potential confounding through comparison of two independent cohorts (pre-diagnosis and post-diagnosis) [24] .
We expanded on these studies by performing a detailed analysis of patients with bladder cancer, including pre-and post-diagnosis HRQoL assessments for each patient, and evaluating more granular data regarding disease stage, treatment and time since diagnosis. Furthermore, we were able to compare these patients with matched controls, in a population that has numerous competing comorbidities (that could negatively affect HRQoL and activities of daily living). With this rigorously defined cohort, we conducted a thorough investigation into disease-specific characteristics that may impact HRQoL. Similarly to Reeve et al. [5] and Kent et al. Fig. 1 Adjusted health-related quality of life changes from baseline to follow-up of controls and patients with bladder cancer, stratified by stage. *P < 0.05. **P <0.01; ***P < 0.001.
© 2017 The Authors BJU International © 2017 BJU International 553 [25] , but in contrast to Fung et al. [24] , we observed a significant decline in HRQoL in PCS, but not MCS scores. Deficits were most pronounced in the specific sub-domains of bodily pain, role physical, and general health, with the largest declines among cases with MIBC in physical health scores (all with >2 point changes [clinically meaningful difference]). These deficits were similar to those observed in a variety of other cancer conditions, including colorectal cancer, lung Role Physical General Health Fig. 3 Adjusted health-related quality of life changes from baseline to follow-up of controls and patients with bladder cancer, stratified by time since diagnosis. *P < 0.05. **P <0.01; ***P < 0.001.
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We also investigated predictors of significant declines in mental and physical HRQoL. Depression appeared to be a strong predictor of decline in both domains, an expected finding given the strong link between depression and mental/ physical health [26] . Additional predictors of MCS score decline included former or never-smoker status (with a stronger effect noted among former smokers), while a diagnosis of chronic sciatica and distant depression appeared to be protective. These findings may reflect coping mechanisms that impact mental HRQoL. For example, patients with distant depression or chronic sciatica may have developed strong coping mechanisms which dampen the impact of a cancer diagnosis on mental health. Protective mechanisms for physical HRQoL decline included hypertension and atherosclerosis. These conditions may predispose to worse physical HRQoL at baseline, which diminish the impact of a cancer diagnosis on further physical decline.
Other prospective studies have investigated HRQoL differences between bladder cancer cases and representative community samples of non-cancer controls. Among 823 cases and 2 037 controls, patients with NMIBC and MIBC reported similar worse functioning than controls across all domains using the European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 cancer-specific instrument [27] . This is in contrast to our findings, which revealed significant differences between NMIBC and MIBC for physical function, with patients with NMIBC having a 2-point decrement and those with MIBC a 5-point decrement between baseline and follow-up. Differences between our findings may be attributable to similarity of treatment strategies in the EORTC QLQ-C30 study, with the majority of patients in that study undergoing cystectomy. In the present study, patients with NMIBC were more likely to undergo non-cystectomy treatment, which probably influenced HRQoL.
Certainly, treatment can negatively impact HRQoL. In a meta-analysis of 29 studies evaluating cystectomy, HRQoL remained similar or improved compared with pre-cystectomy [2] . By contrast, HRQoL among patients with NMIBC showed that mental health was significantly worse than SF-36 norms in the USA at diagnosis, but PCS score was unchanged over a 1-year period [4] . Lack of differences in HRQoL after treatment may be related to the pre-treatment baseline (which was not included). Understanding HRQoL changes before and after treatment may represent a more realistic depiction of the impact of cancer on overall HRQoL. The present study was able to address this concern and investigated the role of treatment on HRQoL by stratifying patients into two groups: cystectomy or no cystectomy. In contrast to previous studies, in which minimal impact on HRQoL was observed, the present study revealed significant decrements in physical functioning as well as vitality and social functioning scores in patients undergoing cystectomy compared with controls and patients undergoing noncystectomy treatment. The negative impact on HRQoL among cases treated with cystectomy is often understated. Patients who undergo cystectomy have higher suicide rates compared with the general population; in particular, patients aged ≥80 years are at increased risk of suicide, which may be related to worse mental HRQoL [28] . An increased risk of suicide may be related to the striking decrease in social functioning noted in the present study. In contrast to those undergoing cystectomy, patients undergoing non-cystectomy treatment had decrements in several physical domains (general health, role physical) but minimal impact on mental health domains. Changes in HRQoL among patients with NMIBC paralleled these findings.
In addition to disease stage and treatments, HRQoL can be influenced by time since diagnosis, given the potential for adaptation and coping. A comparison between 259 patients who underwent cystectomy or non-cystectomy treatment revealed no differences in long-term (>2 year) HRQoL using the cancer and disease-specific FACT-Bl questionnaire [29] . In the present study we evaluated short-term HRQoL (within 2 years of diagnosis) and the impact of diagnosis and treatment on HRQoL may differ if follow-up was extended. The majority of domains did not differ based on time since diagnosis, although role physical scores appeared to improve by 1 year. This domain involves role limitations attributable to physical health such as limiting time at work, difficulty performing work, or accomplishing less than you would like. Recovery may be prolonged after surgery (or intravesical treatments/intense surveillance), and therefore improvements from baseline may not occur until 1 year post-diagnosis in this specific subdomain. To further investigate longitudinal trends, future research should assess long-term HRQoL in patients with bladder cancer. Finally, an additional consideration is the presence or absence of previous cancer diagnoses. A subset of patients with NMIBC had an additional cancer diagnosis, which may influence their HRQoL when compared with new cancer patients. Although this subset of patients was too small to compare, this consideration should be acknowledged.
The present study represents the first comprehensive evaluation of HRQoL before and after bladder cancer diagnosis and treatment; however, some limitations should be noted. First, our cohort was limited to patients with bladder cancer who were enrolled in Medicare Advantage managed care plans. MHOS participants may not be representative of all older adults residing in SEER areas. While some studies indicate that managed care enrollees are healthier than feefor-service beneficiaries [30, 31] , another study indicated similarities between the groups [32] . Second, the sample size was relatively small among patients with bladder cancer, which may reduce our ability to detect statistically significant HRQoL differences between treatment groups. Third, different HRQoL instruments were used during the study period (SF-36 from 1998 to 2005 and VR-12 from 2006 to 2013). Furthermore, these data do not capture patients with cancer or controls who dis-enrol from their plan or die before follow-up HRQoL survey [33] . HRQoL instruments were not cancer-specific and may lack sensitivity with respect to bladder cancer-specific treatment effects. Furthermore, limited health literacy may be a potential barrier to collecting HRQoL from all patients. Fourth, we were unable to capture unknown confounders in the propensity score model, which may influence our results. Finally, we were unable to incorporate detailed information on treatment (e.g. neoadjuvant chemotherapy) and AJCC stage given constraints of coding and definition changes between 1998 and 2013. The number of patients with MIBC undergoing cystectomy was relatively small, limiting interpretation in this population.
Our current understanding of HRQoL among patients with bladder cancer has several implications for clinical practice. First, clinicians should inform patients who receive treatment that their short-term HRQoL in several domains is likely to decrease, even among those undergoing noncystectomy procedures. HRQoL decrements are expected for patients with NMIBC and MIBC. Setting appropriate expectations is critical to improving patient satisfaction, which has been shown to be linked in a variety of conditions including joint replacement [34] [35] [36] . Second, shared decision-making should incorporate an honest discussion regarding the impact of HRQoL when comparing non-cystectomy treatment with cystectomy. A large study investigating patient participation in shared decision-making showed that the majority of patients wished to engage directly if quality of life was incorporated into the decision-making process [37] . Multidisciplinary clinics should provide all possible options in an unbiased and straightforward manner. Finally, understanding that physical HRQoL is most impacted by the diagnosis and treatment of bladder cancer, irrespective of stage, informs future interventions wishing to address and optimize physical health in patients with bladder cancer. Physical health decrements may be addressed through judicious use of physical therapy and other supportive care interventions, even among patients with NMIBC.
In conclusion, the present study is the first to report treatment and stage-specific HRQoL changes by bladder cancer stage and treatment. The results provide valuable information for researchers interested in future interventions aimed at improving HRQoL in older adults with bladder cancer.
